Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Probiotics (CBM588) for Depression in Hemodialysis Patients
NCT05724511Phase 4Completed
- Sponsor
- China Medical University Hospital
- Start
- Feb 2023
- Primary completion
- Jun 2023
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of clostridium butyricum in major depressive disorder (MDD) and cardiovascular diseases (CVD) (2 arms), sponsored by China Medical University Hospital. Primary endpoint: Change of depression score at 3 months. Started Feb 2023; status: completed.
02
Drugs
clostridium butyricum
03
Conditions
major depressive disorder (MDD)cardiovascular diseases (CVD)
Beyond the preview
Go deeper on NCT05724511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05724511.